Welcome to our dedicated page for Y-Mabs Therapeutics SEC filings (Ticker: YMAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Y-mAbs Therapeutics, Inc. (YMAB) SEC filings archive on this page provides a record of the company’s historical regulatory disclosures as a former Nasdaq-listed issuer and documents its transition to a privately held subsidiary of an affiliate of SERB Pharmaceuticals. While Y-mAbs has since terminated registration of its common stock and suspended its reporting obligations, these filings remain an important source of information for understanding its past operations, capital structure, and corporate transactions.
Among the most significant filings for Y-mAbs are its current reports on Form 8-K. A Form 8-K dated August 5, 2025 describes the Agreement and Plan of Merger between Y-mAbs, Perseus BidCo US, Inc. (Parent), and Yosemite Merger Sub, Inc. (Purchaser), under which Parent agreed to cause Purchaser to commence a cash tender offer for all outstanding shares of Y-mAbs common stock at $8.60 per share. A subsequent Form 8-K dated September 16, 2025 reports the completion of the tender offer and the merger under Section 251(h) of the Delaware General Corporation Law, the resulting change of control, and the conversion of each outstanding share (other than specified excluded shares) into the right to receive the cash merger consideration.
These 8-K filings also explain the delisting and deregistration process. In connection with the merger, Y-mAbs requested that the Nasdaq Global Select Market suspend trading in its common stock and file a Form 25 to remove the shares from listing and registration under Section 12(b) of the Securities Exchange Act of 1934. The Form 25-NSE filed on September 16, 2025 by Nasdaq Stock Market LLC serves as the official notification of removal from listing and/or registration. A later Form 15, filed on September 26, 2025, certifies the termination of registration under Section 12(g) and the suspension of Y-mAbs’ duty to file periodic reports under Sections 13 and 15(d). The Form 15 notes that the approximate number of holders of record at the certification date was one.
Earlier and contemporaneous filings, including Forms 10-K and 10-Q referenced in company press releases, contain detailed financial statements, risk factors, and management discussion and analysis related to Y-mAbs’ commercial-stage biopharmaceutical business. These documents discuss revenue from DANYELZA® (naxitamab-gqgk), research and development expenses for SADA PRIT programs such as GD2-SADA and CD38-SADA, selling, general, and administrative costs, and other operating metrics. While these periodic reports are no longer being updated following deregistration, they provide historical context on the company’s financial profile and R&D investment patterns during its time as a public company.
For those examining equity and compensation structures, the merger-related 8-K details the treatment of stock options, restricted stock units (RSUs), and performance-based RSUs (PSUs) at the effective time of the merger, including cash-out provisions and cancellation of options with exercise prices at or above the merger consideration. Additional filings, such as proxy statements and Section 16 reports (Forms 3, 4, and 5), historically provided insight into director and executive equity holdings and changes in beneficial ownership.
On this page, Stock Titan surfaces Y-mAbs’ historical SEC filings with real-time retrieval from EDGAR and AI-powered summaries that explain the core points of each document in accessible language. Users can quickly identify key merger terms, delisting steps, and financial reporting highlights without reading every page of the underlying forms. For deeper analysis, the full-text filings remain available for review, allowing investors, researchers, and legal or compliance professionals to trace the complete regulatory history of Y-mAbs Therapeutics, Inc. under the former ticker YMAB.
Y-mAbs Therapeutics director and 10% owner Johan Wedell-Wedellsborg reported multiple disposals tied to a completed merger. On September 16, 2025, Purchaser completed a tender offer and merged Y-mAbs into an indirect wholly owned subsidiary of Perseus BidCo US, Inc., with each outstanding share cancelled for $8.60 cash per share. The reporting person’s direct and indirect common shares, restricted stock units and stock options were cancelled and converted into cash payments under the Merger Agreement: ordinary shares and RSUs were exchanged for $8.60 per share, while options were cashed out for the excess of $8.60 over each exercise price; options with exercise prices at or above $8.60 were cancelled without consideration. The Form 4 reflects zero continuing share ownership.
John LaRocca, SVP, General Counsel & Secretary of Y-mAbs Therapeutics (YMAB), reported transactions tied to the companys merger completed on 09/16/2025. Pursuant to the Merger Agreement, outstanding restricted stock units (RSUs) and stock options were cancelled and converted into cash payments: RSUs (21,500) were settled for cash at $8.60 per share, and outstanding options were converted into cash equal to the excess of $8.60 over the option exercise price where applicable. Options with an exercise price equal to or above $8.60 were cancelled for no consideration. The filing shows zero shares and zero options beneficially owned by the reporting person after the transactions, and that Y-mAbs became an indirect wholly owned subsidiary of the acquiring parent.
Healy James, a Sofinnova-affiliated director of Y-mAbs Therapeutics (YMAB), reported transactions tied to the company's merger. On 09/16/2025 Purchaser completed a tender offer and merged with the issuer, and each outstanding common share was cancelled for $8.60 cash per share. The reporting person disposed of 31,603 shares and 25,080 restricted stock units were converted into cash in connection with the merger. Outstanding stock options were cancelled and converted into cash equal to the excess of $8.60 over each option's exercise price; options with exercise prices at or above $8.60 were cancelled for no consideration.
Y-mAbs Therapeutics filed a series of Form S-8 registration statements registering common stock for employee equity plans. The filings register: 2,799,373 shares for options under the Amended and Restated 2015 Equity Incentive Plan; 2,122,127 shares for the 2018 Equity Incentive Plan; 578,500 shares for options under the 2018 EIP; 700,000 shares for the 2018 Employee Stock Purchase Plan; 8,078,887 shares (3/30/2023); 1,746,884 shares (2/29/2024); and 1,799,532 shares (3/4/2025) under the 2018 EIP.
Y-mAbs Therapeutics filed a post-effective amendment to registration statements on Form S-8 covering multiple employee equity plans. The filing lists prior Form S-8 registrations that reserve specific share amounts: 2,799,373 shares tied to the 2015 plan options and 2018 plan allocations, 2,122,127 shares under the 2018 Equity Incentive Plan, 578,500 shares for outstanding options under the 2018 plan, 700,000 shares for the 2018 Employee Stock Purchase Plan, and additional 2018 EIP authorizations of 8,078,887, 1,746,884 and 1,799,532 shares on later Forms S-8.
Y-mAbs Therapeutics, Inc. filed post-effective amendments to multiple Form S-8 registration statements to register shares for employee equity plans. The filing lists prior Form S-8 registrations: 2,799,373 shares (2019 filing), 8,078,887 shares (2023 filing), 1,746,884 shares (2024 filing) and 1,799,532 shares (2025 filing), each authorized for issuance under the company's 2015 and 2018 equity plans and an employee stock purchase plan.
Y-mAbs Therapeutics announced a merger agreement that converts outstanding equity awards into cash at the Effective Time. The Agreement and Plan of Merger dated
Y-mAbs Therapeutics, Inc. submitted a Form 25 notification indicating the company’s class of securities will be removed from listing and/or registration on the Nasdaq Stock Market LLC. The filing identifies Nasdaq as the exchange and confirms that the Exchange and the Issuer have followed the procedural rules governing removal or voluntary withdrawal under the Securities Exchange Act. The document is a short procedural notice and does not include financial results, reasons for the removal, effective delisting date, or details about alternate trading arrangements.
Y-mAbs Therapeutics, Inc. reports that the tender offer by Perseus BidCo US, Inc. to acquire the company has closed at $8.60 in cash per share. As of the offer’s expiration at one minute after 11:59 p.m. Eastern time on September 15, 2025, 39,827,138 shares had been validly tendered and not withdrawn, representing approximately 87.22% of the then outstanding shares, satisfying the minimum tender condition.
The purchaser accepted all validly tendered shares, and the merger was completed on September 16, 2025 under Section 251(h) of the DGCL, with Y-mAbs surviving as a wholly owned subsidiary of the buyer’s parent. Following the merger, Y-mAbs shares ceased trading on the Nasdaq Global Select Market and will be delisted, and steps will be taken to terminate registration and suspend reporting obligations under the Exchange Act.
FAQ
What is the current stock price of Y-Mabs Therapeutics (YMAB)?
What is the market cap of Y-Mabs Therapeutics (YMAB)?
